Acquisitions and divestitures

6 Months Ended

Jun. 30, 2021

Routine acquisitions

During the six months ended June 30, 2021, the Company acquired dialysis businesses consisting of one dialysis center located in the U.S. and seven dialysis centers located outside the U.S. for a total of $23,890 in net cash, contingent earn-out obligations of $2,694 and deferred purchase price and liabilities assumed of $3,301. The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company’s condensed consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions.

The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. In particular, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of intangibles, leases and certain other working capital items relating to several of these acquisitions are pending final quantification.

The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of the noncontrolling interests assumed in these transactions:


Current assets	$	3,832
Property and equipment	1,853
Other long-term assets	2,259
Indefinite-lived licenses	1,593
Goodwill	28,323
Liabilities assumed	(6,726)
Noncontrolling interests	(1,249)
	$	29,885

Goodwill deductible for tax purposes associated with acquisitions completed during the six months ended June 30, 2021 was $27,159.

Contingent earn-out obligations

The Company has several contingent earn-out obligations associated with acquisitions that could result in the Company paying the former owners of acquired companies a total of up to approximately $42,581 if certain performance targets or quality margins are met over the next one year to five years.

Contingent earn-out obligations are remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the remeasurement recognized in earnings. As of June 30, 2021, the Company estimated the fair value of these contingent earn-out obligations to be $28,342, of which $11,389 is included in other current liabilities and the remaining $16,953 is included in other long-term liabilities in the Company’s consolidated balance sheet.

The following is a reconciliation of changes in contingent earn-out obligations for the three and six months ended June 30, 2021:


	Three months ended June 30, 2021		Six months ended June 30, 2021
Beginning balance	$	28,225	$	30,248
Acquisitions	2,156		2,694
Foreign currency translation	3,055		975
Fair value remeasurements	60		(154)
Payments	(5,154)		(5,421)
Ending balance	$	28,342	$	28,342

Discontinued operations

On June 19, 2019, the Company completed the sale of its DaVita Medical Group (DMG) business to Collaborative Care Holdings, LLC (Optum), a subsidiary of UnitedHealth Group Inc. At close of the DMG sale, the Company's ultimate net sale proceeds remained subject to resolution of certain post-closing purchase price adjustments described in the equity purchase agreement, which adjustments were finalized in the fourth quarter of 2020. During the first six months of 2020, the Company recognized $9,980 in additional tax benefits under the Coronavirus Aid, Relief, and Economic Security Act related to its period of DMG ownership, which were recognized as an adjustment to the Company's loss on sale of the DMG business.